Chao, Fa-An
Chan, Albert H.
Dharmaiah, Srisathiyanarayanan http://orcid.org/0000-0001-7630-3962
Schwieters, Charles D. http://orcid.org/0000-0002-4216-4658
Tran, Timothy H.
Taylor, Troy
Ramakrishnan, Nitya
Esposito, Dominic http://orcid.org/0000-0002-9987-1687
Nissley, Dwight V. http://orcid.org/0000-0001-7523-116X
McCormick, Frank http://orcid.org/0000-0002-6619-7120
Simanshu, Dhirendra K. http://orcid.org/0000-0002-9717-4618
Cornilescu, Gabriel http://orcid.org/0000-0002-1204-8904
Article History
Received: 4 March 2023
Accepted: 19 May 2023
First Online: 2 June 2023
Competing interests
: All authors, except F.M., declare no competing interests. F.M. is a consultant for Amgen, Daiichi, Frontiers Med, Exuma Biotech, Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, PellePharm, Pfizer, P.M.V. Pharma, and Quanta Therapeutics. F.M. is a consultant and co-founder for BridgeBio, Olema Pharmaceuticals, and Quartz. F.M. has received research grants from Daiichi Sankyo and Gilead Sciences and has a current grant from Boehringer-Ingelheim.